Patents by Inventor Stephanie Venn-Watson

Stephanie Venn-Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190240181
    Abstract: Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Applicant: The United States of America as represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20190201362
    Abstract: Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 4, 2019
    Applicant: The United States of America as represented by the Secretary of the Navy
    Inventors: Stephanie Venn-Watson, Mark Baird
  • Publication number: 20190117607
    Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.
    Type: Application
    Filed: October 18, 2018
    Publication date: April 25, 2019
    Inventors: Stephanie Venn-Watson, John Reiner, Richard Lumpkin
  • Publication number: 20180311195
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Application
    Filed: June 25, 2018
    Publication date: November 1, 2018
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20180296518
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 10022347
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20170266144
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Application
    Filed: April 28, 2017
    Publication date: September 21, 2017
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9713600
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 25, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9707199
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 18, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9687461
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 27, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9662306
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: May 30, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9561206
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: February 7, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160324814
    Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
    Type: Application
    Filed: December 21, 2015
    Publication date: November 10, 2016
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160193170
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Application
    Filed: January 7, 2015
    Publication date: July 7, 2016
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160193171
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 7, 2016
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160195558
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 7, 2016
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160193172
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 7, 2016
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Publication number: 20160195559
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Application
    Filed: December 28, 2015
    Publication date: July 7, 2016
    Applicant: United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson